Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Nav

General Info

Geography

Global

Coverage type

Global

Time period covered

01/2009 - 12/2009

Data type

Scientific literature

Keywords

Ischemic heart disease

Citation

Authors

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 study group

Journal

Lancet

Volume

374

Issue

9683

Pages

29-38

Publication year

2009

Suggested citation

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374(9683): 29-38.

DOI

101016S0140673609607388

PMID

19539361

GHDx Entry last modified on: Mar 25, 2025

Header sites

Search form

Main menu

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Nav